Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-small cell lung cancer
H Cao, K Liang, P Liu, J Wang, Y Ji, L Xu… - Oncology and …, 2020 - journals.lww.com
Objective Anlotinib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor,
has confirmed antitumor activity in lung cancer in both in vitro and in vivo assays, and has …
has confirmed antitumor activity in lung cancer in both in vitro and in vivo assays, and has …
[PDF][PDF] Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-small cell lung cancer
H Cao, K Liang, P Liu, J Wang, Y Ji, L Xu… - Oncology and …, 2020 - otm.tjh.com.cn
Non-small cell lung cancer (NSCLC) is the leading cause of cancer morbidity and mortality
wordwide [1]. Approximately 85% of lung cancers diagnosed are NSCLC, and more than …
wordwide [1]. Approximately 85% of lung cancers diagnosed are NSCLC, and more than …